 Janet Kukreja
Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 11 | 2023 | 226 | 4.190 |
Why?
| | Cystectomy | 7 | 2021 | 38 | 3.400 |
Why?
| | Robotics | 3 | 2021 | 93 | 1.400 |
Why?
| | Robotic Surgical Procedures | 3 | 2021 | 115 | 1.300 |
Why?
| | Urology | 2 | 2024 | 56 | 0.850 |
Why?
| | Cystoscopy | 1 | 2021 | 19 | 0.730 |
Why?
| | Urinary Diversion | 1 | 2020 | 12 | 0.710 |
Why?
| | Smoking | 2 | 2019 | 1500 | 0.670 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 201 | 0.660 |
Why?
| | Urogenital Neoplasms | 1 | 2019 | 5 | 0.650 |
Why?
| | Ureter | 1 | 2020 | 35 | 0.650 |
Why?
| | Urinary Bladder | 2 | 2020 | 175 | 0.600 |
Why?
| | Propensity Score | 1 | 2018 | 264 | 0.530 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 121 | 0.510 |
Why?
| | Urologic Surgical Procedures | 1 | 2017 | 107 | 0.490 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 569 | 0.490 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2015 | 59 | 0.470 |
Why?
| | Anxiety | 1 | 2021 | 972 | 0.440 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1005 | 0.440 |
Why?
| | Neoplasm Invasiveness | 3 | 2023 | 481 | 0.340 |
Why?
| | Aged | 11 | 2021 | 22061 | 0.270 |
Why?
| | Quality of Life | 1 | 2018 | 2688 | 0.260 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 379 | 0.260 |
Why?
| | Humans | 20 | 2024 | 129625 | 0.230 |
Why?
| | Prostatic Hyperplasia | 1 | 2024 | 41 | 0.220 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 70 | 0.200 |
Why?
| | Testicular Neoplasms | 1 | 2023 | 102 | 0.200 |
Why?
| | Male | 13 | 2024 | 63670 | 0.190 |
Why?
| | Retrospective Studies | 6 | 2023 | 14522 | 0.190 |
Why?
| | Middle Aged | 8 | 2021 | 31136 | 0.180 |
Why?
| | Office Visits | 1 | 2021 | 86 | 0.180 |
Why?
| | Venous Thrombosis | 1 | 2022 | 177 | 0.170 |
Why?
| | Guideline Adherence | 1 | 2024 | 527 | 0.170 |
Why?
| | Lymph Node Excision | 1 | 2021 | 164 | 0.170 |
Why?
| | Female | 10 | 2021 | 68734 | 0.160 |
Why?
| | Societies, Medical | 1 | 2023 | 744 | 0.160 |
Why?
| | Urinary Catheters | 1 | 2018 | 8 | 0.160 |
Why?
| | Constriction, Pathologic | 1 | 2020 | 234 | 0.150 |
Why?
| | Ciprofloxacin | 1 | 2018 | 30 | 0.150 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5075 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 287 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2021 | 10219 | 0.150 |
Why?
| | Catheter-Related Infections | 1 | 2018 | 72 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 101 | 0.140 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1282 | 0.140 |
Why?
| | Self Report | 1 | 2021 | 799 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1501 | 0.130 |
Why?
| | Postoperative Period | 1 | 2017 | 330 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1271 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 646 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 958 | 0.120 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 998 | 0.110 |
Why?
| | Preoperative Care | 1 | 2017 | 338 | 0.110 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 374 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7052 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2720 | 0.100 |
Why?
| | Research Design | 1 | 2018 | 1045 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1947 | 0.090 |
Why?
| | Time Factors | 1 | 2020 | 6555 | 0.080 |
Why?
| | United States | 2 | 2024 | 13871 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 1705 | 0.080 |
Why?
| | Cohort Studies | 1 | 2018 | 5426 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3394 | 0.070 |
Why?
| | Enoxaparin | 1 | 2022 | 59 | 0.050 |
Why?
| | Pyridones | 1 | 2022 | 158 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 203 | 0.040 |
Why?
| | Adult | 2 | 2021 | 35599 | 0.040 |
Why?
| | Pyrazoles | 1 | 2022 | 404 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 637 | 0.040 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2018 | 27 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 7135 | 0.040 |
Why?
| | Geriatric Assessment | 1 | 2020 | 205 | 0.040 |
Why?
| | Prostate-Specific Antigen | 1 | 2019 | 160 | 0.040 |
Why?
| | Prostatectomy | 1 | 2018 | 103 | 0.040 |
Why?
| | Anticoagulants | 1 | 2022 | 637 | 0.040 |
Why?
| | Prostate | 1 | 2018 | 173 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2018 | 151 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2019 | 539 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 787 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 836 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1203 | 0.030 |
Why?
| | Radiosurgery | 1 | 2019 | 321 | 0.030 |
Why?
| | Quality Improvement | 1 | 2022 | 1101 | 0.030 |
Why?
| | Incidence | 1 | 2018 | 2641 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5415 | 0.020 |
Why?
|
|
Kukreja's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|